A national, seven‐year program has launched to transform Australia’s prevention, diagnosis and treatment of metabolic (dysfunction) associated fatty liver disease (MAFLD), a rapidly growing condition affecting up to one in three adults and the leading cause of chronic liver disease, with no approved drugs currently. Headquartered at the Storr Liver Centre, Westmead Institute for Medical Research, the initiative unites leading researchers and clinicians nationwide, including the Centenary Institute, the University of Sydney’s Charles Perkins Centre, Westmead and Royal Prince Alfred hospitals.
New national research program to tackle fatty liver disease
